- $1.56bn
- $1.29bn
- $16.10m
Brief: uniQure Announces Dosing Of First Patient In Phase I/II Clinical Trial Of AMT-162 For The Treatment SOD1-AlS
UniQure rises on orphan drug status for genetic disorder gene therapy
Brief: UniQure Announces Closing Of Sale Of Manufacturing Facility To Genezen
UniQure rises on updated interim data from genetic disease study
Brief: uniQure Announces Positive Interim Data Update From Phase I/II Trials Of AMT-130 For Huntington’s Disease
Brief: Uniqure Announces Sale Of Commercial Manufacturing Facility To Genezen
Brief: Genezen To Acquire Uniqure's Commercial Gene Therapy Manufacturing Operations In Lexington, Ma
Brief: uniQure Receives FDA Regenerative Medicine Advanced Therapy Designation For Investigational Gene Therapy AMT-130 In Huntington’s Disease
UniQure climbs after trial results for genetic disorder treatment
Brief: uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
Brief: Uniqure - Strategic Reorganization To Focus On Advancing Multiple Clinical-Stage Programs, Sees $180 Million Of Cost Savings Over Next 3 Years
Brief: Uniqure - Cash Position Of Approximately $660 Million As Of September 30, 2023 Expected To Fund Operations Into Q2 2027
UniQure rises on plans to cut about 20% of workforce
Gene therapy maker UniQure to cut about 20% of workforce (updated)
Brief: Uniqure Announces Strategic Reorganization To Reduce Operating Expenses And Support Advancement Of Multiple Clinical-Stage Programs
UniQure to lay off about 20% of workforce
Brief: Uniqure Announces FDA Clearance Of Investigational New Drug Application For AMT-260 Gene Therapy For Refractory Mesial Temporal Lobe Epilepsy
Blackstone, Airbnb rise on S&P 500 inclusion
UniQure slides after mixed data from genetic disease therapy